An Update from The Parkinson Alliance Regarding COVID-19
KINGSTON, N.J. (March 27, 2020) – The Parkinson Alliance is continually monitoring all local, state, and national updates regarding COVID-19 pandemic. The health and safety of our staff and the Parkinson’s community will always be our first concern. We …
Adamas Releases Final Results of Two-Year Phase 3 Trial of GOCOVRI® for Dyskinesia
(February 11, 2020) The longest-running amantadine study to date of the only FDA-approved medicine for dyskinesia indicates GOCOVRI may help people with PD who are struggling to manage levodopa-related motor complications. Read more.
Postponed: Save the Date for the 26th Parkinson’s Unity Walk on April 25, 2020, in Central Park, New York City
In response to the evolving coronavirus disease 2019 (COVID-19) public health situation and with an abundance of caution, The Parkinson Alliance has decided to postpone the 2020 Parkinson’s Unity Walk, scheduled to take place on Saturday, April 25. The …
Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film
January 2, 2020— Sunovion Pharmaceuticals, Inc. issued a press release announcing that its New Drug Application (NDA) for apomorphine sublingual film (APL-130277) has been accepted by the U.S. Food and Drug Administration. This on-demand treatment is b …